Novel Anticancer Drug Protocols
John K. Buolamwini · Alex A. Adjei
феб 2008. · Methods in Molecular Medicine 85. књига · Springer Science & Business Media
E-knjiga
355
Stranica
reportOcene i recenzije nisu verifikovane Saznajte više
O ovoj e-knjizi
We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.
Ocenite ovu e-knjigu
Javite nam svoje mišljenje.
Informacije o čitanju
Pametni telefoni i tableti
Instalirajte aplikaciju Google Play knjige za Android i iPad/iPhone. Automatski se sinhronizuje sa nalogom i omogućava vam da čitate onlajn i oflajn gde god da se nalazite.
Laptopovi i računari
Možete da slušate audio-knjige kupljene na Google Play-u pomoću veb-pregledača na računaru.
E-čitači i drugi uređaji
Da biste čitali na uređajima koje koriste e-mastilo, kao što su Kobo e-čitači, treba da preuzmete fajl i prenesete ga na uređaj. Pratite detaljna uputstva iz centra za pomoć da biste preneli fajlove u podržane e-čitače.
